$CUE _ More DD Company Overview Cue Biopharm
Post# of 29805
(Total Views: 49)
Posted On: 07/21/2025 2:21:13 PM
$CUE _ More DD
Company Overview
Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a new class of injectable biologics designed to selectively modulate disease-relevant T cells. Their platform, Immuno-STAT™, is engineered to treat cancer, autoimmune, and infectious diseases by targeting specific immune respons
Strong clinical data from CUE-101 trials
Multiple catalysts in pipeline
Low float and analyst support
Technical momentum building after recent gains
Partnerships
LG Chem: Co-developing CUE-101 and CUE-102
Ono Pharmaceutical: Collaboration on CUE-401
Albert Einstein College of Medicine: Licensing agreement
Pipeline Highlights
CUE-101
Indication: HPV+ head and neck squamous cell carcinoma
Stage: Phase 1b (monotherapy and in combination with Keytruda)
Recent Results:
50% overall response rate in combination with Keytruda
88% 12-month survival
Median survival of 32 months 1
CUE-102
Indication: WT1+ cancers (colorectal, gastric, ovarian, pancreatic)
Stage: Phase 1b (monotherapy)
CUE-401
Indication: Autoimmune diseases
Stage: Preclinical
Partnership: Ono Pharmaceutical (development and commercialization rights)
CUE-501
Indication: Autoimmune diseases via antiviral T cell-mediated B cell depletion
Stage: Preclinical
Company Overview
Cue Biopharma is a clinical-stage biopharmaceutical company focused on developing a new class of injectable biologics designed to selectively modulate disease-relevant T cells. Their platform, Immuno-STAT™, is engineered to treat cancer, autoimmune, and infectious diseases by targeting specific immune respons
Strong clinical data from CUE-101 trials
Multiple catalysts in pipeline
Low float and analyst support
Technical momentum building after recent gains
Partnerships
LG Chem: Co-developing CUE-101 and CUE-102
Ono Pharmaceutical: Collaboration on CUE-401
Albert Einstein College of Medicine: Licensing agreement
Pipeline Highlights
CUE-101
Indication: HPV+ head and neck squamous cell carcinoma
Stage: Phase 1b (monotherapy and in combination with Keytruda)
Recent Results:
50% overall response rate in combination with Keytruda
88% 12-month survival
Median survival of 32 months 1
CUE-102
Indication: WT1+ cancers (colorectal, gastric, ovarian, pancreatic)
Stage: Phase 1b (monotherapy)
CUE-401
Indication: Autoimmune diseases
Stage: Preclinical
Partnership: Ono Pharmaceutical (development and commercialization rights)
CUE-501
Indication: Autoimmune diseases via antiviral T cell-mediated B cell depletion
Stage: Preclinical
(0)
(0)